- Email: [email protected]
Peptides: A target for new drug development
123
Announcements Peptides: A Target for New Drug Development
Diabetes: Its Therapy and Complications
9-10 November 1987, London, U.K.
3-4 December 1987, London, U.K.
Peptides are now estabilished as the largest group of extracellular messengers in the body and possess a number of attributes which makes them attractive as drug discovery targets. In recent years, a plethora of peptides have been identified as endogenous neurotransmitters, neuromodulators, growth factors and hormones. They have exciting implications in a variety of diseases including endocrinological, cardiovascular, respiratory and oncological diseases, and consequently enormous therapeutic potential. The seminar will cover the major areas of current research into peptides and their capabilities as therapeutic agents and will appeal to R & D personnel in the pharmaceutical industry, basic scientists and clinicians.
Exciting advances are taking place in the understanding of diabetes mellitus. This intriguing disorder is unique among the endocrine deficiency states in that current insulin replacement therapy, although ameliorating symptoms and preventing death from ketoacidosis, does not prevent the long term development of distressing and disabling complications. This Seminar brings together international experts to discuss new developments with particular emphasis on the potential for therapeutic initiatives. These may have a major impact in delaying or preventing the immune-mediated damage to the insulin-producing pancreatic beta cell and in delaying or preventing the development of neuropathy, nephropathy and retinopathy in the established diabetic.
Lipid-Lowering Drugs in Heart Disease Prevention 30 November-1 December 1987, London, U.K.
Diagnostics '87
Compared with other metabolic disorders, the hyperlipidaemias are remarkably common, seriously under-diagnosed and often inadequately treated. Yet without appropriate management, these disorders play a causal and central role in the development of atherosclerosis and coronary heart disease. Progress in the diagnosis and treatment of hyperlipidaemias has increased dramatically in the last few years. In parallel with these advances, there is major activity in both the U.S.A. and Europe aimed at physician education in diagnosing and treating hyperlipidaemia, and this will lead to an enormous increase in the number of patients requiring appropriate and effective therapy. The conference will review these recent advances and will be of interest to those in clinical medicine, preventative medicine and public health, and the pharmaceutical and food industries, as well as to investigators in the field of atherosclerosis research.
10-11 December 1987, Churchill College, Cambridge, U.K. This Seminar, part of the Cambridge Series on Biotechnology, will review the current developments in diagnostic aids and will look at the new technologies to be introduced which may be appropriate in the future. The meeting will be particularly relevant to those in the biotechnology and pharamaceutical industries and will deal mainly with clinical and forensic aspects as well as horticultural and agricultural viewpoints.
Drug Delivery and Drug Targeting Systems 14-15 December 1987, London, U.K. This conference is aimed towards research executives in the pharmaceutical industry, as well as clinicians, pharmacologists and pharmacists. It will
Announcements Peptides: A Target for New Drug Development
Diabetes: Its Therapy and Complications
9-10 November 1987, London, U.K.
3-4 December 1987, London, U.K.
Peptides are now estabilished as the largest group of extracellular messengers in the body and possess a number of attributes which makes them attractive as drug discovery targets. In recent years, a plethora of peptides have been identified as endogenous neurotransmitters, neuromodulators, growth factors and hormones. They have exciting implications in a variety of diseases including endocrinological, cardiovascular, respiratory and oncological diseases, and consequently enormous therapeutic potential. The seminar will cover the major areas of current research into peptides and their capabilities as therapeutic agents and will appeal to R & D personnel in the pharmaceutical industry, basic scientists and clinicians.
Exciting advances are taking place in the understanding of diabetes mellitus. This intriguing disorder is unique among the endocrine deficiency states in that current insulin replacement therapy, although ameliorating symptoms and preventing death from ketoacidosis, does not prevent the long term development of distressing and disabling complications. This Seminar brings together international experts to discuss new developments with particular emphasis on the potential for therapeutic initiatives. These may have a major impact in delaying or preventing the immune-mediated damage to the insulin-producing pancreatic beta cell and in delaying or preventing the development of neuropathy, nephropathy and retinopathy in the established diabetic.
Lipid-Lowering Drugs in Heart Disease Prevention 30 November-1 December 1987, London, U.K.
Diagnostics '87
Compared with other metabolic disorders, the hyperlipidaemias are remarkably common, seriously under-diagnosed and often inadequately treated. Yet without appropriate management, these disorders play a causal and central role in the development of atherosclerosis and coronary heart disease. Progress in the diagnosis and treatment of hyperlipidaemias has increased dramatically in the last few years. In parallel with these advances, there is major activity in both the U.S.A. and Europe aimed at physician education in diagnosing and treating hyperlipidaemia, and this will lead to an enormous increase in the number of patients requiring appropriate and effective therapy. The conference will review these recent advances and will be of interest to those in clinical medicine, preventative medicine and public health, and the pharmaceutical and food industries, as well as to investigators in the field of atherosclerosis research.
10-11 December 1987, Churchill College, Cambridge, U.K. This Seminar, part of the Cambridge Series on Biotechnology, will review the current developments in diagnostic aids and will look at the new technologies to be introduced which may be appropriate in the future. The meeting will be particularly relevant to those in the biotechnology and pharamaceutical industries and will deal mainly with clinical and forensic aspects as well as horticultural and agricultural viewpoints.
Drug Delivery and Drug Targeting Systems 14-15 December 1987, London, U.K. This conference is aimed towards research executives in the pharmaceutical industry, as well as clinicians, pharmacologists and pharmacists. It will